JSMC
AXSM icon

Jess S. Morgan & Co’s Axsome Therapeutics AXSM Stock Holding History

Jess S. Morgan & Co’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$3.52M Sell
78,895
-25,994
-25% -$1.3M 3.06% 15
2022
Q2 		$4.02M Sell
104,889
-2,298
-2% -$72.7K 4.17% 8
2022
Q1 		$4.44M Sell
107,187
-7,338
-6% -$227K 3.23% 8
2021
Q4 		$4.33M Buy
114,525
+1,095
+1% +$40.3K 2.66% 22
2021
Q3 		$3.74M Buy
113,430
+45,595
+67% +$1.78M 2.47% 32
2021
Q2 		$4.58M Buy
67,835
+15,177
+29% +$911K 3.01% 11
2021
Q1 		$2.98M Buy
52,658
+8,190
+18% +$576K 2.09% 31
2020
Q4 		$3.62M Buy
44,468
+5,450
+14% +$408K 2.89% 16
2020
Q3 		$2.78M Sell
39,018
-310
-0.8% -$24.2K 2.77% 17
2020
Q2 		$3.24M Sell
39,328
-3,074
-7% -$237K 3.51% 5
2020
Q1 		$2.5M Buy
42,402
+36,902
+671% +$3.01M 3.24% 16
2019
Q4 		$568K Buy
+5,500
New +$222K 0.56% 37

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Jess S. Morgan & Co's AXSM Position: Q3 2022 in Review

Jess S. Morgan & Co reduced its Axsome Therapeutics (AXSM) stake by 25% in Q3 2022, selling an estimated $1.3M and leaving 78,895 shares worth $3.52M. The position accounts for 3.06% of the portfolio, ranked #15.

Jess S. Morgan & Co first reported a position in AXSM in Q4 2019 and has held it in 12 quarters since. The position peaked at $4.58M in Q2 2021. 189 funds tracked by Wall St. Rank hold AXSM as of Q3 2022.

  • Jess S. Morgan & Co held 78,895 shares of Axsome Therapeutics worth $3.52M as of Q3 2022.
  • Jess S. Morgan & Co sold 25,994 Axsome Therapeutics shares in Q3 2022, an estimated $1.3M.
  • Axsome Therapeutics made up 3.06% of Jess S. Morgan & Co's portfolio in Q3 2022, its #15 holding.
  • Jess S. Morgan & Co first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 12 quarters since.
  • Jess S. Morgan & Co's Axsome Therapeutics position peaked at $4.58M in Q2 2021.
  • 189 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2022.

Based on Jess S. Morgan & Co's 13F filing for Q3 2022, filed 21 Oct 2022.